Geron Corp
Gesloten
SectorGezondheidszorg
1.38 2.99
Overzicht
Wijziging aandelenprijs
24u
Min
1.35
Max
1.44
Inkomsten | 25M -3.6M |
|---|---|
Verkoop | 3.8M 52M |
EPS | -0.005 |
Winstmarge | -7.026 |
Werknemers | 258 |
EBITDA | 27M 3.8M |
Aanbevelingen | Strong Buy |
|---|---|
12 Maanden Prognose | +196.3% upside |
Volgende Winsten | 5 aug 2026 |
|---|
Marktkapitalisatie | -147M 860M |
|---|---|
Vorige openingsprijs | -1.61 |
Vorige sluitingsprijs | 1.38 |
Nieuwssentiment
By Acuity
4%
96%
1 / 342 Rangschikking in Healthcare
Geron Corp Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Over Geron Corp
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
